Gilead says Glaxo venture’s HIV patent invalid
Healthcare 2019-12-10 11:57 pmBy Cat Fredenburgh | Melbourne
Please login to bookmark Close

US biotech giant Gilead has struck back at a patent infringement lawsuit brought by a specialist HIV pharmaceutical company majority owned by GlaxoSmithKline, saying the patent at the centre of the lawsuit is invalid.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au